"Koselugo (Selumetinib, AstraZeneca), the first drug used for childhood neurofibromatosis, a rare disease, is stepping up its challenge." Although he had a hard time at the HIRA in March, efforts to register health insurance have continued since then, such as supplementing data and reapplying for benefits. Starting next year, expectations for the registration are growing as the drug price negotiation period for drugs designated as drugs subject to rapid screening, such as Koselugo, is shortened. According to the industry on the 30th, Koselugo has continued its efforts to register benefits by submitting supplementary data since it was non-reimbursement in March.

Since then, the HIRA has also conducted a